Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD.
Eron JJ, et al.
J Infect Dis. 2004 Mar 15;189(6):1075-83. doi: 10.1086/381707. Epub 2004 Mar 2.
J Infect Dis. 2004.
PMID: 14999611
Clinical Trial.